Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Trustpilot boosts outlook on strong first half, shares spark

(Sharecast News) - Trustpilot Group boosted its full-year outlook on Tuesday, after a strong first half saw earnings beat expectations. Revenues at the London-listed consumer reviews platform rose 23% - or by 21% on a constant currency basis - to $122.8m in the six months to 30 June, while bookings increased 19% to $140m.

Adjusted earnings before interest, tax, depreciation and amortisation surged 70% to $18m, which Trustpilot said was ahead of internal expectations. Pre-tax profits were 45% higher at $3.7m.

The Danish firm said it had benefited from new tools, such as AI review summaries, during the period, as well as enterprise customer wins, including Barclays, Boots, Lindt and Vimeo.

Looking to the full year, Trustpilot said second-half trading had so far been ahead of expectations.

As a result, it reiterated its outlook for high-teens constant currency revenue growth for the full-year, but said the adjusted EBITDA margin would be in line with the first half, ahead of expectations.

Adrian Blair, chief executive, said: "Our first half results demonstrate the momentum of our platform and the strength of our business model.

"Our expanded use of AI in operations helped drive significant efficiencies, contributing to a notable improvement in adjusted EBITDA margin and strong free cash flow generation.

"We remain confident in the long-term growth opportunities ahead."

The FTSE 250 group also said on Tuesday that it would commence a £30m share buyback.

At 0810 BST, the shares were up 10.4% at 221.54p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.